This announcement does not concern the awarding of a public contract within the meaning of the public procurement coordination directive (2014/24 / EU) or antitrust law. In the interest of the broadest possible information for interested pharmaceutical companies, this announcement is made in the supplement to the Official Journal of the European Union. The process name "open procedure" used in the context of the present notice text (section IV.1.1.) Is due to the requirements of the notice form. This, as well as the use of the medium "TED", does not involve any submission to procurement regulations, the validity of which is not mandatory by law or award regulations. It is a framework contract with an accession option that relates to various active ingredients.
The contract covers medicinal products that contain the active ingredient adalimumab.
The contract covers medicinal products that contain the active ingredient dronedarone.
The contract covers drugs that contain the active ingredient dutasteride.
The contract covers drugs that contain the active ingredient combination dutasteride + tamsulosin.
The contract covers drugs that contain the active ingredient etanercept.
The contract covers drugs that contain the active ingredient combination ezetimibe + atorvastatin.
The contract covers medicinal products that contain the active ingredient formoterol in the dosage form aerosol.
The contract covers medicinal products that contain the active ingredient formoterol in the inhalation powder (IHP) dosage form.
The contract covers medicinal products that contain the active ingredient ginkgo flavone glycosides Gingko biloba leaf extract (acetone-water extract, standardized 240 mg daily dose).
The contract covers medicinal products that contain the active ingredient hydroxyzine.
The contract covers medicinal products that contain the active ingredient methyldopa.
The contract covers medicinal products that contain the active ingredient alitretinoin.
The contract covers drugs that contain the active ingredient metronidazole in a topical dosage form.
The contract covers medicinal products that contain the active ingredient combination norethisterone + estradiol in an oral dosage form.
The contract covers medicinal products that contain the active substance posaconazole.
The contract covers medicinal products that contain the active substance prednisone in the dosage form prolonged-release tablet.
The contract covers medicinal products that contain the active ingredient propiverine in the dosage form hard capsule with modified active ingredient release (HVW).
The contract covers medicinal products that contain the active ingredient silodosin.
The contract covers drugs that contain the active ingredient teriparatide.
The contract covers medicinal products that contain the active ingredient tizanidine.
The contract covers drugs that contain the active ingredient tolvaptan.
The contract covers drugs that contain the active ingredient combination amlodipine + valsartan + hydrochlorothiazide.
The contract covers medicinal products that contain the active ingredient bortezomib (with the exception of manufactured parenteral preparations from finished medicinal products).
,
The contract covers drugs that contain the active ingredient bupropion (except Lifestyle AM).
The contract covers medicinal products that contain the active ingredient cinacalcet.
The contract covers medicinal products that contain the active ingredient active ingredient colistimethate in an inhalation dosage form in the potency: 1,662,500 IU.
The contract covers medicinal products that contain the active ingredient dienogest.
The contract covers drugs that contain the active ingredient distigmine bromide.